| ARES |
Report |
After-Tax RI/share (Q2 2026) |
BEAT |
pred ~$1.31 vs. cons $1.28 |
MEDIUM |
| ARES |
Report |
FRE (Q2 2026) |
BEAT |
pred ~$490M vs. cons $483M |
MEDIUM |
| ARES |
Report |
FPAUM (Q2 2026) |
BEAT |
pred ~$420B vs. cons $414B |
MEDIUM |
| ARES |
Guide |
FRE Margin (FY 2026) |
BETTER |
guide ~43.0-43.2% vs. cons 42.7% |
MEDIUM |
| ARES |
Guide |
European Perf. Income (FY 2026) |
UNCHANGED |
guide ~$350M vs. cons embedded |
HIGH |
| ARES |
Guide |
Fundraising / Mgmt Fees (FY 2026) |
BETTER |
guide record year reaffirmed vs. cons $4.29B |
MEDIUM |
| ARES |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.5% |
— |
MEDIUM |
| ARES |
Return |
5-day cumulative residual |
+2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — sell-side FRE revisions upward + short covering sustains the move; capped by modest beat magnitude and partial pre-pricing from BX/KKR sector sympathy |
MEDIUM |